178 results
6-K
EX-99.1
GLPG
Galapagos NV
8 Apr 24
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
9:27am
to assess the safety, efficacy and feasibility of point-of-care manufactured GLPG5101 and GLPG5201 in patients with relapsed/refractory NHL, and relapsed … /refractory CLL and RT, respectively. The primary objective of the Phase 1 part of the studies is to evaluate the safety and preliminary efficacy
6-K
EX-99.2
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
, our drug candidates mentioned in this report are investigational; their efficacy and safety have not been fully evaluated by any regulatory authority … our ongoing and planned clinical research programs may not support registration or further development of our product candidates due to safety
6-K
EX-99.1
GLPG
Galapagos NV
23 Feb 24
Galapagos announces full year 2023 results and outlook for 2024
6:41am
.
GLPG5301 (BCMA CAR-T) in relapsed/refractory multiple myeloma (rrMM)First patients dosed in the PAPILIO-1 Phase 1/2 study to evaluate the safety … of the Pharmaceutical Risk Assessment Committee (PRAC) to add safety measures for the JAK inhibitors class of medicines.
Based on topline results from
6-K
EX-99.1
GLPG
Galapagos NV
16 Feb 24
Galapagos presents at EBMT-EHA annual meeting 2024
6:00am
chronic lymphocytic leukemia (rrCLL) and patients with Richter transformation (RT). Further, previously disclosed safety, efficacy and feasibility data … ); Auditorium 1
Phase 1/2, Multicenter, Open-Label Study to Evaluate Feasibility, Safety and Efficacy of Point-of-Care–Manufactured Anti-BCMA CAR T-Cell
6-K
EX-99.1
t05i g1c5brc87vv
6 Feb 24
Galapagos completes transaction to transfer Jyseleca® business to Alfasigma
6:00am
6-K
EX-99.1
edomwdlba8m2
4 Jan 24
Galapagos signs agreement to transfer Jyseleca® business to Alfasigma
4:05pm
6-K
EX-99.1
yxpvvu6f1s7
21 Dec 23
Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301
4:03pm
6-K
EX-99.1
3yl liujadqmt
12 Dec 23
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101
7:02am
6-K
EX-99.1
gdya k4ogg
12 Dec 23
Current report (foreign)
6:00am
6-K
EX-99.1
jikpc8okv
3 Nov 23
Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023
8:26am
6-K
EX-99.1
5w2474b5nscyra0svt5
2 Nov 23
Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma
7:15am
6-K
EX-99.1
cm6r9
30 Aug 23
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus
6:31am
6-K
EX-99.1
qqc2wl6c7ne8oha
4 Aug 23
Galapagos announces first half-year 2023 financial results
4:05pm
6-K
EX-99.2
8qh8 n2zl6
4 Aug 23
Galapagos announces first half-year 2023 financial results
4:05pm
6-K
EX-99.1
phqij3f4
12 Jun 23
Current report (foreign)
7:32am
6-K
EX-99.1
r7e rpe2npj55
25 May 23
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with dermatomyositis
5:49pm
6-K
EX-99.1
b3h32j0
23 May 23
Galapagos demonstrates commitment to immunology with new data in rheumatoid arthritis at EULAR 2023
7:30am
6-K
EX-99.1
7rbi0atpx67xrli1bd
5 May 23
Galapagos announces first quarter 2023 financial results
4:05pm
6-K
EX-99.1
xsu 1p20u8k
2 May 23
Current report (foreign)
4:15pm